We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

24 hedge funds and large institutions have $979K invested in Statera Biopharma, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

4% less funds holding

Funds holding: 25 → 24 (-1)

20% less capital invested

Capital invested by funds: $1.22M → $979K (-$237K)

Holders
24
Holders Change
-1
Holders Change %
-4%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$32.5K
2
LTFS
Ladenburg Thalmann Financial Services
Florida
+$8.99K
3
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$2.93K
4
Wells Fargo
Wells Fargo
California
+$978
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$587

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$197K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$31K
3
Citadel Advisors
Citadel Advisors
Florida
-$22K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$12.1K
5
Neuberger Berman Group
Neuberger Berman Group
New York
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
26
PNC Financial Services Group
Pennsylvania
– +$587 +75 New
1
2

STAB Hedge Fund Activity: Q4 2014 in Review

24 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2014, worth a combined $979K — down 20% from $1.22M a quarter earlier.

Fund positioning in STAB was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 4 trimmed.

The largest buyer was Virtu KCG Holdings, adding an estimated $32.5K. The largest seller was Sabby Management, cutting an estimated $197K.

  • 24 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2014, down from 25 in Q3 2014.
  • Funds reported $979K of Statera Biopharma, Inc. Common Stock stock for Q4 2014, down 20% quarter-over-quarter.
  • 5 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2014 and 5 closed out, a net change of 0 holders.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2014 was Virtu KCG Holdings, an estimated $32.5K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q4 2014 was Sabby Management, an estimated $197K sold.

Based on aggregated 13F filings for Q4 2014.